Simulations Plus (NASDAQ:SLP - Get Free Report) had its price target decreased by analysts at KeyCorp from $40.00 to $25.00 in a report issued on Monday,Benzinga reports. The brokerage currently has an "overweight" rating on the technology company's stock. KeyCorp's price target would indicate a potential upside of 43.51% from the company's current price.
Several other equities research analysts have also recently commented on SLP. William Blair reaffirmed an "outperform" rating on shares of Simulations Plus in a research report on Tuesday, June 3rd. Craig Hallum lowered their target price on Simulations Plus from $45.00 to $36.00 and set a "buy" rating on the stock in a research note on Friday, June 13th. Wall Street Zen upgraded Simulations Plus from a "sell" rating to a "hold" rating in a research report on Monday, April 28th. JMP Securities reaffirmed a "market perform" rating on shares of Simulations Plus in a research report on Wednesday, June 18th. Finally, BTIG Research lowered their price target on Simulations Plus from $41.00 to $25.00 and set a "buy" rating for the company in a research report on Monday, July 7th. Two research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Simulations Plus has an average rating of "Moderate Buy" and an average target price of $31.25.
Read Our Latest Research Report on SLP
Simulations Plus Price Performance
Simulations Plus stock opened at $17.42 on Monday. The company has a market cap of $350.33 million, a P/E ratio of 49.77 and a beta of 0.83. The firm's 50 day simple moving average is $24.77 and its 200-day simple moving average is $28.37. Simulations Plus has a fifty-two week low of $16.72 and a fifty-two week high of $44.33.
Insider Transactions at Simulations Plus
In related news, Director Walter S. Woltosz sold 20,000 shares of the firm's stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $33.51, for a total value of $670,200.00. Following the completion of the sale, the director owned 3,344,157 shares of the company's stock, valued at $112,062,701.07. This trade represents a 0.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 19.40% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in SLP. Kopion Asset Management LLC lifted its position in Simulations Plus by 22.7% in the second quarter. Kopion Asset Management LLC now owns 156,401 shares of the technology company's stock worth $2,729,000 after buying an additional 28,980 shares during the last quarter. Rhumbline Advisers grew its position in shares of Simulations Plus by 2.1% during the first quarter. Rhumbline Advisers now owns 66,222 shares of the technology company's stock worth $1,624,000 after buying an additional 1,334 shares in the last quarter. Woodline Partners LP lifted its stake in Simulations Plus by 32.1% in the first quarter. Woodline Partners LP now owns 13,239 shares of the technology company's stock valued at $325,000 after buying an additional 3,220 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Simulations Plus during the first quarter worth $255,000. Finally, Uniplan Investment Counsel Inc. lifted its position in Simulations Plus by 141.8% during the first quarter. Uniplan Investment Counsel Inc. now owns 144,202 shares of the technology company's stock worth $3,536,000 after buying an additional 84,562 shares during the period. 78.08% of the stock is owned by institutional investors.
Simulations Plus Company Profile
(
Get Free Report)
Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Simulations Plus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Simulations Plus wasn't on the list.
While Simulations Plus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
